Why Kallel was founded:
10-5-26
Modern medicine has made staggering strides in treating individual diseases, yet aging itself remains the single greatest risk factor for nearly every chronic condition we face. At Kallel, we believe that longevity should not be a luxury, and extending healthspan should not require waiting decades for entirely novel molecules to clear the pharmaceutical pipeline. We founded our non-profit to fundamentally reshape how translational longevity research is funded, accelerated, and brought to the public.
The status quo in drug development is structurally ill-equipped for aging. Traditional investor-backed pharmaceutical companies are driven by profit margin, which creates an economic barrier: no corporation can justify the millions of dollars required to run clinical trials on off-patent, generic drugs. As a result, safe, inexpensive compounds that show promise in laboratory longevity experiments are routinely left stranded before they ever reach human clinical trials.
Kallel exists to bypass this commercial bottleneck. Operating as a non-profit frees us from traditional market constraints. We rely on the enduring power of human altruism; our vision is a self-sustaining research ecosystem fueled by a foundation endowment from philanthropic donors who believe that lifespan and healthspan extension is a fundamental public good.
Our work is driven by two core pillars:
Democratizing Longevity Treatment: We are launching adaptive clinical trials utilizing safe, affordable, FDA-approved generic drugs that have already demonstrated significant life-extending effects in the NIA-funded Interventions Testing Program (ITP). By focusing on generics, we can bypass the decades-long drug discovery lag and deliver accessible, affordable interventions to people much sooner.
Increasing lifespan and healthspan: Rooted in the belief that preventative medicine is the key to aging well, we look for interventions that not only extend life but actively delay the onset of age-related conditions such as reduced cognition, hypertension, type 2 diabetes, and signs of frailty, including reduced mobility and strength.
Educating the public and the medical community: Discovery alone is not enough; accessibility requires awareness. We are committed to actively translating and sharing our findings with both the general population and healthcare providers, ensuring that everyday people can understand, advocate for, and immediately benefit from these therapies.
Creating an Open Hub for Longevity Research: We are uniting evolutionary biology, high-throughput innovation, and open science to fuel our clinical pipeline. Crucially, we are committed to making all of our research data freely and publicly available to the global aging research community, ensuring our breakthroughs benefit the entire field. This open ecosystem will be driven by two key efforts:
Decoding extreme longevity: Nature has already solved the puzzle of aging in remarkable ways. We study the genomics of long-lived species to extract biological blueprints that can inform human therapeutics. Highlighted by our recent work on the genomic analysis of Jonathan, the world’s oldest living land animal, published in X123 these insights guide our target discovery.
Enhancing generic drug discovery: We will accelerate the identification of synergistic generic drug combinations by enhancing high-throughput drug screening with AI in model systems, such as the WormBot platform using the roundworm C. elegans. This will rapidly feed new candidate combinations directly into the ITP pipeline, while also making them freely available to the aging research community.
Our work converges on a single, actionable mission: extending human lifespan and healthspan. This is achievable by discovering combinations of existing FDA-approved drugs that can extend human lifespan and healthspan, while simultaneously uncovering novel targets from long-lived species. With our first adaptive clinical trial targeted for 2027 and our comparative genomic pipelines expanding rapidly, we are moving from basic biology to clinical reality. Join us in building a future where longevity is within reach for everyone.